Current Status of BTKi Treatment for CLL/SLL in China
ConditionCLL/SLL
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorThe First Affiliated Hospital with Nanjing Medical University
About this trial
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years;
Patients with a confirmed diagnosis of CLL/SLL;
Received BTK inhibitor treatment between February 2023 and February 2024.
Disqualifiers
Patients with other types of lymphoma;
Cases deemed unsuitable for inclusion in this study by the investigators.
Trial population
CLL/SLL Patient who receiving BTKi treatment
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
BTK inhibitor
DrugBTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
Treatment groups
1,000 Participants
are divided into 1 treatment groupGroup A: BTK inhibitor treated1 intervention
Trial outcomes
Primary outcomes
1
Patient characteristics of those receiving BTKi treatment
Describe the patient characteristics of those receiving BTKi treatment, including age, gender, etc
Time frame
up to one yearSecondary outcomes
1
overall response rate
Assessed according to the iwCLL2018 criteria
Time frame
up to one year2
Incidence of adverse reactions
Assessed according to the CTCAE 5.0 criteria
Time frame
up to one yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov